CClinicalTrials.gg
RecruitingNCT07483255Updated Jul 23, 2026

A Phase II Trial of Fetal Embolization for Vein of Galen Malformation

An interventional study of Fetal embolization of vein of Galen malformation using Target XL and XXL Detachable Coils in Vein of Galen Malformations, sponsored by Darren Orbach. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Darren Orbach · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

This is a prospective, single-arm non-randomized interventional study of fetuses to assess the efficacy and safety of fetal embolization of VOGM. Subjects will receive a one-time study intervention of fetal embolization, at or after 34 weeks of gestation. After delivery, neurological assessments will be performed every 6 months for 2 years (adjusted for gestational age). Data will be compared to historical cohorts.

Read the detailed description

The study involves a single fetal intervention of maternal transuterine, fetal transcranial torcular puncture and median prosencephalic vein embolization for fetuses with vein of Galen malformations (VOGM) with a falcine sinus (FS) width of >= 7 mm (study population). Detachable platinum coils (Target XL and XXL Detachable Coil, Stryker Neurovascular) will be used to pack the prosencephalic varix. This procedure will take place in an OR at Boston Children's Hospital. Data regarding pre-delivery, delivery and post-delivery status will be collected until the subject is discharged from the hospital. After delivery, neurological assessments will be performed on the child every 6 months for 2 years (adjusted for gestational age). Data will be compared to historical cohorts.

02

Conditions studied

  • Vein of Galen Malformations
03

In context

Lead sponsor

Darren Orbach is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  1. Pregnant woman carrying a fetus harboring a vein of Galen malformation in whom the straight sinus or falcine sinus draining the prosencephalic varix measures 7 mm or more on fetal MRI (medio-lateral diameter measured at the narrowest point of the sinus along the rostral-caudal axis, assessed on a T2-weighted coronal or axial slice).
  2. Fetal gestational age of 34 weeks or more at the time of the planned fetal intervention, as determined by clinical information and evaluation of first ultrasound. The suitability for fetal treatment, in terms of technical/positional factors, will be assessed on a case-by-case basis by the MFM, ultrasonographer, and neurointerventionalist participating in the study.
  3. Anatomic diagnosis of fetal vein of Galen malformation. Various cerebrovascular conditions, such as dural sinus malformation and pial arteriovenous fistula, can result in dilated intracranial vascular structures being visualized in utero. Similarly, fetal dilatation of the vein of Galen can occasionally be seen without the presence of an arteriovenous lesion at all, as a benign venous variant. This condition is readily distinguishable sonographically from VOGM by virtue of the presence of dilated arterial feeding pedicles, and by the presence of an arterial waveform within the varix. This study is aimed solely at fetuses with an established diagnosis of vein of Galen malformation.

Exclusion criteria

Exclusion Criteria:

  1. Extensive fetal brain parenchymal injury/gliosis, i.e. >10% of supratentorial brain volume (SFP presentation). In some cases, significant bihemispheric cerebral parenchymal injuries are seen at the time of initial fetal diagnosis of vein of Galen malformation (SFP cohort). Such fetuses rarely survive, but if they do, are profoundly neurodevelopmentally impaired: typically blind, mute, quadriparetic, often with unremitting intractable seizures, and permanently bed-bound and uncommunicative. As there is no realistic possibility of achieving a good neurological outcome in such patients, fetuses with diffuse bihemispheric brain injury will be excluded.
  2. Irreversible fetal non-brain organ injury (e.g. hydrops fetalis as a manifestation of heart failure, a finding which portends fatal outcome in fetuses with vein of Galen malformation).
  3. Fetus with VOGM in whom the straight sinus or falcine sinus draining the prosencephalic varix measures less than 7 mm on fetal MRI (T2-weighted coronal or axial slice, medio-lateral diameter measured at the narrowest point of the sinus along the anterior-posterior axis), fitting fetal MRI criteria for likely evolution into the IT cohort
  4. Severe maternal obesity pre-pregnancy as defined by body mass index (BMI) of 40 or greater
  5. Fetuses with major extracranial congenital anomalies
  6. Evidence of preterm labor, rupture of membranes or abruption
  7. Maternal coagulopathy: INR > 1.2; PT/PTT above normal ranges for the lab; platelets \<100
  8. Any maternal use of anticoagulants, whether prophylactic or therapeutic.
  9. Prior maternal medical history that would preclude epidural anesthesia
  10. Multi-fetal pregnancy
  11. Placenta previa or accreta
  12. Participation in another fetal study that influences maternal and fetal morbidity and mortality
  13. Known maternal hypersensitivity to 316LM stainless steel
  14. Supine hypotensive syndrome
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Single Arm

    This is an open-label, single-arm study. Fetal subjects will undergo a one-time intervention of fetal embolization of vein of Galen malformation.

    Device: Fetal embolization of vein of Galen malformation using Target XL and XXL Detachable Coils

Interventions

  • DeviceFetal embolization of vein of Galen malformation using Target XL and XXL Detachable Coils

    The study involves a single fetal intervention of maternal transuterine, fetal transcranial torcular puncture and median prosencephalic vein embolization. Detachable platinum coils (Target XL and XXL Detachable Coil, Stryker Neurovascular) will be used to pack the prosencephalic varix.

06

What researchers measure

Primary outcomes

  1. Efficacy of fetal embolization for patients with vein of Galen malformations

    Primary outcome/endpoint: mortality measured from birth to day 30 of life.

    Time frame: Birth to day 30 of life

Secondary outcomes

  1. Safety of fetal embolization of patients with vein of Galen malformations

    Safety outcomes/endpoint: the incidence of the following serious adverse events (SAEs) from Day 0 (the day of fetal intervention) till birth, as measured by number of events experienced across the number of participants enrolled: 1. Fetal intraparenchymal hemorrhage with mass effect, likely related to the procedure 2. Fetal territorial ischemic infarct, likely related to the procedure 3. Procedure-related fetal hemorrhage, either intracranial or extracranial, requiring transfusion 4. Maternal hemorrhage requiring blood transfusion 5. Procedure-related placental injury requiring urgent Caesarian section

    Time frame: Day of fetal intervention to 24 months of age

  2. Brain parenchymal injury

    The incidence of brain parenchymal injury on the first postnatal scan will be collected and compared to a historical cohort that did not undergo fetal intervention.

    Time frame: Birth to first postnatal scan

  3. Neurodevelopmental milestones at 6 months

    A neurological assessment will be performed at 6 months adjusted gestational age using Vineland Adaptive Behavior Scales and the Receptive-Expressive Emergent Language Test. Scores for enrolled participants will be compared to scores from a historical cohort at a similar age.

    Time frame: Birth through 6 months

  4. Neurodevelopmental milestones 6 months through 24 months

    Neurological assessments will be performed from 6 months adjusted gestational age to 24 months adjusted gestational age using Vineland Adaptive Behavior Scales and the Receptive-Expressive Emergent Language Test, Child Behavior Checklist, DAYC-2 cognitive assessment, and the Bayley examination (if seen in person). Scores for enrolled participants will be compared to scores from a historical cohort at a similar age.

    Time frame: 6 months through 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07483255
Lead sponsor
Darren Orbach
Responsible party
Darren Orbach (Chief, Neurointerventional Radiology, Boston Children's Hospital) — Sponsor-investigator
First posted
Mar 19, 2026
Start date
Jul 20, 2026
Primary completion
Dec 2030 (estimated)
Completion
Dec 2032 (estimated)
Last update
Jul 23, 2026

Study contacts

Darren Orbach, MD PhD
Contact
Darren.Orbach@childrens.harvard.edu
617-355-5012
Darren Orbach, MD PhD
principal investigator · Boston Children's Hospital, Boston, MA 02115

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion